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Abstract
Trying to conceive and being pregnant is an emotional period for those involved. In the majority 
of patients suffering from inflammatory bowel disease, maintenance therapy is required during 
pregnancy to control the disease, and disease control might necessitate introduction of new 
drugs during a vulnerable period. In this updated consensus on the reproduction and pregnancy 
in inflammatory bowel disease reproductive issues including fertility, the safety of drugs during 
pregnancy and lactation are discussed.
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1. Introduction
Inflammatory bowel diseases (IBD) have a high prevalence in 
young individuals, so that reproductive issues freqently arise. 
This updated consensus paper addresses these issues and is 
aimed to optimize preconceptional counseling in patients with 
inflammatory bowel disease and to promote a European perspec-
tive on the management of pregnancy in patients with IBD and 
its dilemmas.
This document is based on the European Consensus on repro-
duction in inflammatory bowel disease, reached by the European 
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Crohn’s and Colitis Organization (ECCO) at a meeting held in 
Prague in February 2010.1 The Consensus is grouped into four parts: 
fertility; pregnancy and delivery; outcome of children and manage-
ment of IBD during pregnancy; and lactation. The strategy to reach 
the Consensus on the guideline revisions involved seven steps.
Guideline statements of the 2010 Consensus were analyzed sys-
tematically by the chairs of the working parties. After careful con-
sideration the following chapters of the first Consensus were not 
addressed in this Consensus: influence of IBD on sexuality, oral con-
traceptive use in IBD, venous thromboembolism risk in pregnancy, 
cervical cancer screening, and endoscopy during pregnancy. Guideline 
statements selected for change and questions unresolved by the 2010 
ECCO Consensus were distributed to the working party members.
In parallel, the working parties performed a systematic literature 
search of their topic with the appropriate key words using Medline/
Pubmed and the Cochrane Database, as well as their own files. The 
evidence level (EL) was graded according to the Oxford Centre for 
Evidence Based Medicine of 2011.2
Provisional guideline statements on their topic were then writ-
ten by the chairs of the working groups and posted on a web blog. 
Discussions and exchange of the literature evidence among the 
working party members was then performed on the web blog. This 
process was supervised by C.J.W. and F.M.
After agreement within the working parties, the statements were 
posted for review by the working parties and national representa-
tives from 18 different countries (n = 25).
After the first voting, all consensus statements that did not 
reached the approval rate above 80% were revised.
On December 6th 2013, the working parties met in Vienna to agree 
the statements. Technically this was done by projecting the statements 
and revising them on screen until a consensus was reached. Consensus 
was defined as agreement by >80% of participants, termed a Consensus 
Statement and numbered for convenience in the document.
The final document on each topic was written by the chairs in con-
junction with their working party. The final text was edited for con-
sistency of style by C.J.W. and F.M. and then circulated and approved 
by the participants. In some areas the level of evidence is generally 
low, which reflects the paucity of evidence in reproduction-related 
issues. Consequently expert opinion is included where appropriate.
2. Fertility
2.1. Influence of disease activity on fertility in 
females and males
Patients with quiescent Inflammatory bowel disease (IBD) are as 
fertile as the general population.3,4 
Patients with IBD have fewer children than the general popu-
lation, but this is related to voluntary childlessness.4,5 Patient’s 
choice is reported to be the main reason for voluntary childless-
ness6; patient’s knowledge of pregnancy in IBD is often poor,7 
which in itself is associated with negative views.8 Crohn’s disease 
(CD) might decrease fertility both directly, by inducing inflam-
mation in the fallopian tubes and ovaries and by perianal disease 
causing dyspareunia,9 and indirectly through surgical interventions 
and associated tubal adhesions. In addition there are recent data 
to suggest a reduction in ovarian reserve function as estimated 
by serum levels of anti-Müllerian hormone in CD, particularly in 
active disease and women over age 30.10,11 Many women with IBD 
choose to stay childless voluntarily and this exceeds the number of 
those experiencing fertility issues, as also demonstrated in a recent 
meta-analysis.12,13
2.2. Influence of medication on fertility and 
conception
There are no data reporting the effects of medication on female 
fertility. In men, sulfasalazine therapy causes a reversible decrease in 
sperm motility and count.
The effect is dose related and it is unaffected by supplemental folic 
acid.14–17 Azathioprine (AZA) did not influence sperm quality in 18 
male IBD patients who used AZA for at least 3 months.18 In addi-
tion, no effect was seen on the outcomes of pregnancies fathered by 
IBD patients on thiopurines.19 Methotrexate (MTX) produces oli-
gospermia, this will improve within a few months after stopping the 
drug.20 MTX is however contraindicated for men aiming to father a 
child. Infliximab (IFX) seems to affect semen quality by reducing motil-
ity in a small group of patients; however data are contradictory as 
sperm concentration increased after infusion.21,22 Furthermore, men 
with spondylarthropathies tended to have better sperm qualities when 
receiving anti-TNF therapy.23 The outcome of 10 pregnancies indirectly 
exposed to IFX through the male partner resulted in nine live births, 
one miscarriage, and no congenital malformations were reported.22
2.3. The influence of abdominal surgery on fertility 
in males
Men who undergo ileoanal pouch surgery for ulcerative colitis 
(UC) may experience retrograde ejaculation and erectile dysfunction. 
However, overall no change or even an improvement in sexual 
function occurs after surgery.24–27 The effect of surgery on fertility 
rates in men has not been studied.
2.4. The influence of abdominal surgery on fertility 
in females
ECCO Statement 2A
There is no evidence that ulcerative colitis or inactive 
Crohn’s disease affect fertility [EL3]. However, active 
Crohn’s disease may reduce fertility and hence it is advis-
able to strive for remission [EL3]. High levels of voluntary 
childlessness in women with Inflammatory bowel disease 
indicate the need for better education [EL4]
ECCO Statement 2B
There is no evidence that medication affects fertility in 
females [EL4]. In males sulphasalazine causes reversible 
oligospermia [EL3]
ECCO Statement 2C
Pelvic surgery may lead to impotence or ejaculatory prob-
lems in men [EL4]
ECCO Statement 2D
Pelvic and, to a lesser extent, abdominal surgery for IBD 
increases the risk of subfertility in females [EL1]. A lapa-
roscopic approach to ileal pouch anal anastomosis  may 
lower infertility rates compared with an open surgical 
approach [EL2]
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Evidence suggests that subfertility (failure to conceive within a 
year) is increased amongst women with IBD who have undergone 
pouch surgery.4,9,24,28–33
Several meta-analyses found that ileal pouch-anal anastomosis 
(IPAA) conferred a 2-3-fold increased risk of infertility compared 
with medical management.34–36 Higher rates of hydrosalpinx, 
destruction of fimbria, and tubal obstruction following pelvic sur-
gery37 are the most likely mechanisms for subfertility after surgery 
for IBD.
There is now some evidence from retrospective studies that 
infertility rates after laparoscopic IPAA surgery are lower than 
those seen after open IPAA surgery,38,39 which may be primar-
ily related to a reduction in adhesions.40 There are, however, no 
data to support the approach of subtotal colectomy with rectal 
stump and ileostomy during the childbearing years followed by 
IPAA later in life to help reduce infertility rates. Relatively rare 
ileostomy complications could arise during pregnancy, such as 
obstruction or stoma-related problems.41,42 Rates of successful in 
vitro fertilization after IPAA are similar to those in women with-
out IBD and surgery.43
3. Pregnancy and delivery outcome of 
mothers
3.1. The influence of pregnancy on the activity of 
inflammatory bowel diseases
When conception occurs during a period of remission, about 
a third of patients relapse during pregnancy which is similar to 
the relapse risk in non-pregnant CD patients.44,45 On the other 
hand, if conception occurs at a time of active disease, two-thirds 
have ulcerative colitis (UC). In UC, females’ higher relapse rates 
were observed during the first 2 trimesters. This underscores the 
importance of advising patients to conceive at a time of remis-
sion.46–49 Pregnancy may influence the overall course of IBD 
positively; with increasing parity, the need for surgical interven-
tion decreases. Furthermore, patients with a previous pregnancy 
require fewer resections and the interval between operations 
tends to be longer when compared with nulliparous women with 
CD.32,50 Mothers with CD seem also to have a lower relapse rate 
in the years after pregnancy compared with the years before preg-
nancy, but specific confounders such as smoking have not been 
investigated or ruled out in multivariate analyses.51–53 A  small 
retrospective study has demonstrated that quality of life deter-
mined by the Short Inflammatory Bowel Disease Questionnaire 
improved during pregnancy in 50% of women.54 Pregnancy has 
an effect on the immune system, which may contribute to these 
findings.55
3.2. The mode of delivery and outcomes
The mode of delivery should primarily be dictated by obstetric 
necessity. Advice from a gastroenterologist and/or the colorectal 
surgeon should give the obstetrician and patient a balanced view on 
the consequences of a postpartum sphincter/pelvic floor impairment 
with respect to present and future bowel function. Cesarean section 
is recommended in patients with perineal disease or in case of active 
disease with rectal involvement. Although some clinicians advocate 
cesarean section for all CD patients, it seems reasonable to allow 
vaginal delivery for women with quiescent or mild disease as no evi-
dence can be found in the literature in favour of either approach.56,57 
Episiotomy should be avoided if possible because a high rate of peri-
anal involvement has been reported; nevertheless it is preferable to 
an uncontrolled laceration.58 Vaginal delivery was not a risk factor 
for developing fecal incontinence in a large UK study.59 In contrast, 
a much smaller survey of women with CD (likely subject to selection 
and response bias) found an increased risk of incontinence after vagi-
nal delivery compared with healthy controls.60 The risk of develop-
ing de novo perianal disease is not increased after vaginal delivery in 
comparison with women who underwent cesarean section.61 A recent 
large retrospective review of 6 797 669 deliveries and 2882 (0.04%) 
deliveries among patients with concomitant diagnosis of CD showed 
that perianal disease predicts severe perianal laceration.62
IPAA is regarded as a relative indication for Caesarean sec-
tion.29,63–65 A person with an IPAA is deemed borderline incontinent 
and depends more on an intact sphincter and pelvic floor function for 
maintaining fecal continence. Some studies report worse physiological 
and/or clinical outcomes,29,66 but the literature is not unanimous on 
this.34,58,67–69 The choice of delivery method post IPAA should be made 
after careful consideration of the patient’s situation and preferences, as 
data on continence post vaginal delivery are equivocal. Patients with an 
ileorectal anastomosis have an intact rectal function, but are at risk of 
recurrent disease and further surgery. There are no data to suggest that 
these patients would benefit from cesarean sections.
There is a one-in-five risk that a woman with UC will need a colec-
tomy and may be a candidate for an ileal pouch anal anastomosis 
during her fertile period. The risk of sphincter injuries is highest at 
the first delivery. Counseling a patient with regard to mode of delivery 
must be on an individual basis, mainly adhering to obstetric princi-
ples. Those patients considered at particularly high risk for needing 
pouch surgery in the future (such as previous admission with acute 
severe colitis, or those needing biological therapy) might be a group 
for whom particularly careful discussion on the mode of delivery is 
ECCO Statement 3A
If conception occurs at a time of quiescent disease, the 
risk of relapse is the same as in nonpregnant women 
[EL3]. Conception occurring at a time of active disease 
increases the risk of persistent activity during pregnancy 
[EL3]. Pregnancy may influence the course of inflamma-
tory bowel disease [EL3]
ECCO Statement 3B
The mode of delivery is subject to a multidisciplinary 
approach and should primarily be governed by obstetric 
indications [EL5]
ECCO Statement 3C
Cesarean section is indicated in active perianal disease 
or active rectal involvement [EL5]. An ileoanal pouch or 
an ileorectal anastomosis in women with IBD is a relative 
indication for a cesarean section but the decision should 
be made on an individual basis [EL5]
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appropriate. Patients with a colostomy, ileostomy or continent ileos-
tomy can deliver vaginally, but if the obstetric risk is increased for 
other reasons, there should be a low threshold for cesarean section.
3.3. The risk of relapse after delivery
About a third of IBD mothers experience a flare after delivery47 
but this risk is not significantly higher when compared with the risk of 
having a flare while not pregnant. A recent prospective study has sug-
gested that in contrast to women with CD, women with UC may have 
higher rates of flares postpartum,49 but these results require verifica-
tion. Patients with IPAA have a 20–30% chance of developing distur-
bances of pouch function (increased bowel frequency and a decrease in 
continence) in pregnancy and particularly in the third trimester. These 
changes usually resolve completely during the puerperium.63,68,70,71
4. Pregnancy and delivery: outcome of 
children
4.1. Risk of developing IBD with one or both parents 
having IBD
Positive family history is an important predictor of the lifetime risk 
for acquiring IBD.72–74 Around 5.5-22.5% of patients with IBD have 
another family member also affected with the disease.75,76 The overall 
risk for children with one parent affected with IBD is 2–13 times higher 
than in the general population.77,78 For children among whom both par-
ents have IBD, the risk of disease occurrence during their lifetime rises 
above 30%.79,80 The relative risk for a sibling of a CD patient to become 
affected is 13 to 36 higher than the general population, and for a sibling 
of a UC patient the relative risk is 7 to 17 higher compared with the gen-
eral population. Translating into absolute numbers, hereby assuming 
an overall incidence in Europe and North America of 10 new cases per 
100 000 for UC and 5–6 new diagnoses per 100 000 for CD, this gives 
a risk of 2–3% for a sibling of a CD patient and 0.5–1% for a sibling 
of a UC patient.81 Risk increases significantly if the parent affected with 
CD is the mother, and if the offspring is female.82,83 Transmission of CD 
from the affected mother to daughter, in the familial IBD population, 
implies a specific female sex inheritance pattern, which could not be 
demonstrated for UC, for the affected fathers or for the affected male 
offspring.83 Patients with IBD and a family history tend to present at 
an earlier age, and show an increased concordance in disease type (CD 
or UC) and probably in disease location. In contrast, the severity of the 
disease does not differ between familial or sporadic disease.73
4.2. Outcome of pregnancy and adverse outcome 
of offspring
Women with IBD have an increased overall risk for adverse preg-
nancy outcomes. The most consistently described are preterm deliv-
ery (before 37 weeks of gestation), low birthweight (LBW) (<2500 g) 
and small for gestational age (SGA) birth.73,84–90
Concerning delivery mode, most studies have shown significantly 
increased frequency of cesarean section, both elective and performed 
as an emergency intervention.44,86,89–91 The risk of adverse pregnancy 
outcome seems to be similarly increased in UC and CD.85,89,90,92,93
Very few studies have evaluated whether there is an effect of IBD on 
first-trimester outcome of pregnancy (i.e. increased chance of miscar-
riage or an ectopic pregnancy) and whether there is an effect on the rate 
of complications of pregnancy (placental abruption, chorioamnionitis, 
preeclampsia/eclampsia, placenta previa, premature and prolonged rup-
ture of membranes). However, a few studies report there is an increased 
rate of miscarriage, both spontaneous and induced. Additional data 
on the frequency of complications of pregnancy and labour are very 
inconsistent, precluding a meaningful conclusion.44,89–91,93
Disease activity at conception and during pregnancy seems 
to be an important risk factor for adverse pregnancy outcomes. 
Several recent studies have examined the impact of disease activ-
ity on pregnancy outcomes using proxy measures such as IBD-
related surgery and hospitalization before and during pregnancy, 
change of IBD medication, and low weight gain during preg-
nancy.85–87,89,90,93–95 The majority have revealed that IBD mothers 
with active disease at conception and during pregnancy have a 
higher risk of preterm birth, low birthweight and small for gesta-
tional age birth compared with IBD mothers with disease in remis-
sion. Other predictors of adverse pregnancy outcomes in IBD, 
besides disease activity, include familial history of IBD, disease 
localization and IBD surgery.84,86,88
Maternal IBD seems to have no major adverse effects on the 
infant born at term. In these infants, low APGAR (Appearance, 
Pulse, Grimace, Activity, Respiration) scores and presence of seizures 
were not more common in the offspring of mothers with IBD. For 
these infants there is no increased risk of neonatal death rates and 
admission on an intensive care unit.
 Although some studies revealed an association between congeni-
tal malformations and maternal UC, particularly limb deficiencies 
and urinary malformation,74,96,97 this has not been replicated in large 
studies, regardless of disease activity.86,88–90,95
ECCO Statement 3D
There is no increased risk of a flare in the postpartum 
period for women with CD remaining on their mainte-
nance therapy [EL 2]. In women with UC the risk of a post-
partum flare may be increased [EL4]
ECCO Statement 4A
Children of parents with IBD have an increased risk of 
developing inflammatory bowel disease. The risk is higher 
for Crohn’s disease, and if both parents are affected [EL 3]. 
In Crohn’s disease, transmission is more common from 
mother to child than from father to child, and female off-
spring are at higher risk than male offspring [EL 3]
ECCO Statement 4B
Cesarean delivery is more frequent in women with IBD; 
and there is an increased risk of low birthweight and pre-
term birth [EL2]. Disease activity at conception or during 
the pregnancy is associated with preterm birth and low 
birthweight [EL 3]
ECCO Statement 4C
Adverse fetal outcomes such as low APGAR scores, sei-
zures or admission to an intensive care unit and death, 
are not increased in babies born at term [EL2]. The risk 
of congenital abnormalities in offspring from women 
with inflammatory bowel disease does not seem to be 
increased [EL2]
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4.3. Effect of medication used for IBD treatment 
during pregnancy on the health and development of 
the infant, including the vaccination program
Several studies have demonstrated that mothers with IBD using 
thiopurines during pregnancy have an increased risk of preterm 
birth, LBW and SGA.74,98–101 However, the investigators failed to take 
disease activity into consideration, which is the risk factor most com-
monly associated with these adverse pregnancy outcomes.
In contrast to these findings, a number of recent cohort studies 
revealed that thiopurine use during pregnancy does not affect the risk 
of preterm birth, low birthweight or SGA.92,102–105 Moreover, long-
term follow-up studies (3–4 years) reported that offspring exposed 
to thiopurines during pregnancy had normal mental and physi-
cal development and no increased risk of infections during child-
hood.106,107 However, with respect to congenital anomalies, the safety 
of thiopurines during pregnancy is still being debated.108 Although 
some studies have demonstrated an association between intrauterine 
thiopurine exposure and congenital abnormalities,96,99,109 this has not 
been replicated in several larger studies.100,103,104,107,110,111
One prospective investigation, which included 28 pregnant IBD 
mothers on thiopurines, revealed that 60% of the offspring were 
born with anemia (hemoglobin level below 10 mmol/l). Further stud-
ies are needed to clarify this association.104
The incidence of childhood malignancies or risk for other specific 
disorders due to long-term fetal exposure to IBD medication remains 
unknown.
With respect to medications used by fathers with IBD, no increase 
in major malformations was found (3 vs 2.2 %) in offspring from 
115 pregnancies where the fathers were exposed to thiopurines at 
the time of conception.19
With respect to biological agents, several studies have shown that 
treatment with anti-TNF drugs does not increase the risk of adverse 
pregnancy outcomes.102,112–114 As IFX has been detected in infants up 
to 6 months after birth, there are concerns about immune system 
development, rate of infections and also possible negative implica-
tions on the response to vaccination. For non-live vaccines there have 
been no reported adverse events,115 and immune responses to routine 
childhood vaccinations were appropriate.116 Similarly, the response 
of adult patients treated with adalimumab (ADA) to pneumococ-
cal and influenza vaccinations was normal in rheumatoid arthritis 
patients.117 Therefore, current vaccination strategies with non-live 
vaccines for infants who have been exposed to anti-TNF in utero 
do not differ from those for unexposed infants. This does not apply 
to live vaccines such as rotavirus, oral polio and Bacille Calmette–
Guerin (BCG) vaccinations which are contraindicated in immune-
suppressed individuals. There is a single case report of a child, from 
a mother exposed to IFX during pregnancy, that died at 4.5 months 
due to disseminated BCG infection after receiving the vaccination at 
3 months.118 Live vaccines should only be given to infants in the sec-
ond half of the first year, when it is expected that no detectable IFX 
or ADA should be present,or no detectable anti-TNF is found when 
measured. Also, timing of the last dose of IFX and ADA should be as 
late in the second trimester as possible (around 24–26 weeks of ges-
tation), to maintain remission but to limit the transport of the drug 
to the fetus.119–123 Whether this applies to certolizumab pegol needs 
to be investigated, since this medication is not actively transported 
across the placenta. The levels of other drugs used for IBD treatment 
in infants (such as AZA) are probably not elevated and will not influ-
ence vaccination programs; however, data are lacking.
5. Management of IBD during pregnancy
5.1. The influence of IBD activity on IBD 
management
Several studies have demonstrated that most pregnancies in 
women with IBD will be uncomplicated, if the patient is in remission 
or has only minor disease activity at the time of conception.124–126 
A meta-analysis by Miller in more than 1300 female UC patients 
and 700 CD patients clearly demonstrated that normal pregnancies 
are observed in 83% of women with CD (71–93% in individual 
studies) and in 85% of women with UC (76–97% in individual stud-
ies).127 Malformations were observed in about 1% of all pregnan-
cies, and the frequency of spontaneous miscarriages and stillbirths 
was in the same range as observed in the healthy normal popula-
tion. In contrast, several studies demonstrate that the frequency 
of normal pregnancies is reduced and the frequency of adverse 
outcomes of pregnancy is increased, when pregnancies take place 
in phases with active inflammatory bowel disease.128–132 However, 
ECCO Statement 4D
Fetal exposure to most IBD medications is considered of 
low risk to the child, except for methotrexate and thalido-
mide [EL2]. Fetal exposure to thiopurines is not associ-
ated with an increased risk of infections in the first year 
[EL3]. The risk of infection with anti-TNF agents alone or 
in combination with immunomodulators is controversial 
[EL4]
ECCO Statement 5A
Appropriate treatment of IBD should be maintained in 
those patients who wish to conceive, in order to reduce 
the risk of flares during pregnancy [EL5]. Acute flares dur-
ing pregnancy carry a high risk of adverse maternal and 
fetal outcome, and are best treated appropriately and 
without delay to prevent these complications [EL3]
ECCO Statement 4E
Since detectable levels of anti-TNF in the offspring are 
present in the first 6 months at least, live vaccines should 
be avoided in this period [EL5]. Current vaccination strate-
gies with non-live vaccines do not differ from those for 
infants unexposed in utero to anti-TNF agents [EL4]
ECCO Statement 4F
Timing of the last dose of the anti-TNF drug should con-
sider both maternal disease activity and drug placental 
transfer. When considered appropriate by the clinician 
and the patient, to limit the transport of the anti-TNF to 
fetus, the anti-TNF drug should be discontinued around 
gestational week 24–26 [EL3]
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increased rates of preterm birth and low birthweight in IBD patients 
also occur unrelated to disease activity.92 Moreover, compared with 
pregnant IBD patients with inactive disease, women with a relapse 
during pregnancy have infants with significantly shorter gestation 
time and lower birthweight,84,95,130,131,133 increased neonatal intensive 
care unit admission, and low APGAR score.87 In addition, disease 
activity increases the risk for thromboembolic events and emergency 
cesarian delivery.134 Therefore, conception should take place during 
disease remission and active disease should be treated aggressively.
5.2. Medical treatment of IBD and adverse 
pregnancy outcomes
The use of 5-ASA derivatives (with the exception of formula-
tion with dibutylphthalate coating), corticosteroids, thiopurines, and 
biologicals is not associated with significant maternal or neonatal 
adverse outcomes in pregnant IBD patients. For a summary of the 
risks of frequent IBD medications used during pregnancy and cur-
rent ECCO recommendations, see Table 1.
5.2.1. Aminosalicylates, sulfasalazine
Case series, population-based cohort studies,47,135–138 and two meta-
analyses139,140 did not demonstrate an increased risk for early preg-
nancy adverse outcomes such as miscarriage and ectopic pregnancy. 
Some trials have demonstrated a higher rate of premature birth, still-
birth, and low birthweight; however, the confounding factor of active 
disease is difficult to delineate.135 Animal and human data and the 
recent meta-analysis140 did not demonstrate teratogenic effect. A small 
increase in the risk for congenital malformations has only been shown 
in the meta-analysis by Cornish et al., but could have been the result 
of active disease.139 As sulfasalazine treatment interferes with folate 
absorption, supplementation is recommended with a higher dose of 
folic acid than recommended in general (2 mg/day of folate).
The mesalazine formulation Asacol® (Procter & Gamble 
Pharmaceuticals, OH, USA) with dibutyl phthalate coating has been 
recently downgraded from FDA Category B to C.  Dibutyl phtha-
late has been found in increased concentrations in a patient using 
the drug,141 and in animal studies an increased risk of malforma-
tions in the male urogenital tract has been observed, but this has not 
been described in a humans.142 Nevertheless, high level of phthalates 
exposure is possibly associated with precocious puberty in humans143 
and, therefore, a switch to a different 5-ASA should be considered 
for a pregnant IBD patient.
5.2.2. Corticosteroids
All corticosteroids (systemic, oral and topical) can cross the placenta 
to the fetus but are rapidly converted by placental 11-hydroxygenase 
to less active metabolites, resulting in low fetal blood concentration. 
As short-acting prednisone, prednisolone and methylprednisolone 
are more efficiently metabolized by the placenta and therefore reach 
lower concentrations in the fetus than the longer-acting dexametha-
sone and betamethasone, the former molecules are preferred for the 
treatment of maternal conditions necessitating glucocorticosteroids. 
Adverse effects on pregnancy outcome, shown in animal studies, 
have not been confirmed in humans.47,86,144 However, the risk for 
orofacial malformations (cleft lip/palate) is increased in offspring of 
mothers receiving steroids in the first trimester of pregnancy,145,146 
though this increased risk is small and not confirmed by all stud-
ies.147 In addition, a recent large population-based study compris-
ing 51 973 pregnancies exposed to corticosteroids during the first 
trimester also failed to find an increased risk of orofacial malforma-
tions.148 Also, there are case reports of neonatal adrenal suppression 
due to the use of corticosteroids in the late pregnancy of womwn 
with IBD.149 There is just one case series of eight CD patients treated 
with budesonide, which did not find an increased risk of adverse 
pregnancy outcome.150 Nevertheless, it remains important to always 
consider the risks and benefits when prescribing steroids for the 
mother. Although not clearly demonstrated in IBD patients, the risk 
of maternal complications such as hypertension, diabetes and pre-
eclampsia seems to be increased during pregnancy,151,152 which in 
turn can be associated with an unfavorable pregnancy outcome.
ECCO Statement 5B
Most drugs used for the treatment of IBD are considered 
to be of low risk during pregnancy [EL3]. However, metho-
trexate and thalidomide, are contraindicated [EL3]
Table 1.  ECCO overview on drug risk during pregnancy and lacata-
tion.
Drug During pregnancy During lactation
Mesalazine Low risk Low risk
Sulfasalazine Low risk Low risk
Corticosteroids Low risk Low risk, 4 h 
delay before 
breastfeeding is 
advised
Thiopurines Low risk, limited  
data on 6-TG
Low risk
Anti-TNF agents Low risk, consider  
stopping around week 24 
in patients with sustained 
remission. See text
Probably low  
risk, limited data
Methotrexate Contraindicated Contraindicated
Thalidomide Contraindicated Contraindicated
Metronidazole Avoid first trimester Avoid
Ciprofloxacin Avoid first trimester Avoid
6-TG: 6-thioguanine
ECCO Statement 5C
In cases of relapse, depending on the disease phenotype 
and activity, 5-ASA or corticosteroids are the preferred 
therapies [EL5]. Anti-TNF agents can be considered to 
treat flares in appropriate situations [EL5]
ECCO Statement 5D
Infliximab and adalimumab cross the placenta and their 
use beyond the second trimester results in neonatal lev-
els exceeding maternal levels [EL3]. This exposure can 
be limited by stopping the treatment around gestational 
week 24–26 when considered appropriate by the clinician 
and the patient [EL3]
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5.2.3. Azathioprine (AZA) and 6-mercaptopurine (6-MP)
AZA and its metabolite 6-MP are purine analogues which interfere 
with the synthesis of adenine and guanine ribonucleotides. AZA 
crosses the placenta and its metabolites have been determined in 
fetal red blood cells.153 In a recent study evaluating prospectively the 
pharmacokinetics of thiopurines during 30 pregnancies, a metabolic 
shift towards higher 6-methylmercaptopurine (6-MMP) production 
was shown in mothers but without clinically relevant toxicity. In cord 
blood, thiopurines’ active metabolites (6-TG) were detected in levels 
reaching on average 50% of maternal levels.104 In this study, 60% 
of infants had anemia and, therefore, immediate postnatal blood 
count assessment of children exposed to thiopurines in utero might 
be considered. Fetal exposure to AZA and 6-MP has been reported in 
several hundreds of cases.99,100,136,154 The adverse pregnancy outcomes 
described in these studies were an increased rate of spontaneous 
miscarriage, preterm delivery and low birthweight,99,155 which could 
have been caused by the underlying disease rather than by the use of 
thiopurines.156 More recent controlled studies102,103,106,111 and a meta-
analysis157 reported no increased risk for adverse pregnancy outcome 
in IBD patients treated during pregnancy with thiopurines, compared 
with pregnancy outcomes of IBD patients without this treatment. An 
association with preterm birth, but no congenital malformations, and 
low birthweight was shown in one recent meta-analysis.98 A few cases 
of immunologic and hematologic abnormalities and chromosomal 
aberrations in newborns and infants, probably caused by immuno-
suppression, have been described.100 However, a prospective study 
following 30 children exposed to thiopurines in utero revealed nei-
ther developmental nor immunologic abnormalities in these children 
during a median follow-up of 3.8 years.107
It has been reported that 6-T6 passes through the placenta,158 
and in the absence of further safety data it should not be used during 
pregnancy.
5.2.4. Ciclosporin and tacrolimus
Both ciclosporin and tacrolimus are widely used for treatment and 
prevention of graft vs host reaction after bone marrow transplan-
tations, and to inhibit rejection after solid organ transplantation. 
Therefore most of the data on pregnancy outcome are derived from 
these patients.
For ciclosporin, a meta-analysis of 15 studies with 410 pregnant 
patients did not find an increased rate of congenital malforma-
tions.159 Similar, but fewer, data exist for tacrolimus.160
Evidence on the use of ciclosporin in IBD is limited to small series 
of women who had severe relapses during pregnancy.133,148,161 With 
tacrolimus just a single case report of UC patient was published.162 No 
congenital malformations were described; the outcomes were compli-
cated with prematurity and low birthweight, but it is very difficult to 
differentiate the impact of severe disease from the effect of drug itself.
5.2.5. Methotrexate (MTX) and thalidomide
Both drugs are teratogenic and contraindicated in pregnancy, and 
therefore barrier methods to prevent pregnancy during therapy 
with MTX are advised. Though normal pregnancy outcomes were 
reported,163 exposure to MTX, particularly during the first trimester, 
may result in miscarriage, growth retardation, fetal loss and congen-
ital malformations, including craniofacial anomalies, limb defects 
and CNS abnormalities.164 If conception should accidentally occur, 
termination of pregnancy should be discussed, but not necessarily 
performed. Prospective mothers should be instructed to stop MTX 
immediately and start high-dose folate replacement. The intracellu-
lar metabolites of MTX, methotrexate polyglutamates, have a long 
half-life and take about 6 weeks to reach steady state or to com-
pletely wash out. To avoid exposure to MTX it should be stopped 
in both females and males, at least for 3–6 months before trying to 
conceive. Use of thalidomide has been associated with major fetal 
malformations involving limbs, ears, eyes, and neural tube defects, 
and with neonatal mortality rate of 40%.165 There are no data on the 
recommended wash-out period prior to conception for thalidomide.
5.2.6. Biological therapy
IFX and ADA both are IgG1 antibodies and can cross the placenta, par-
ticularly in the second and third trimester.120 Concerning IFX, detectable 
levels were documented in one case report166 and in three studies com-
prising 11, 12 and 11 infants, respectively.121,123 At birth levels were, as 
expected, higher in infants and were measurable for 2 to 7 months.167 
Although data are still limited, there is growing evidence that IFX expo-
sure is of low risk in pregnancy, at least for the early outcomes including 
the absence of teratogenic effects.112 In addition, the preliminary data 
from the PIANO study also suggest that the use of anti-TNF agents is 
safe during pregnancy. In this multicenter, prospective study, pregnancy 
outcomes of 797 pregnancies of IBD patients exposed, respectively, to 
thiopurines monotherapy, anti-TNF agents monotherapy, and combi-
nation therapy, were compared with a control group of IBD patients 
without immune-suppressive medication or anti-TNF treatment. No 
differences in the rate of congenital malformations and other short-
term adverse pregnancy outcomes were found between the pregnan-
cies exposed to thiopurines or anti-TNF monotherapy and the control 
group. However, an increased infection rate during the first year of life 
has been reported in the group of infants exposed in utero to the combi-
nation of thiopurines and anti-TNF agents [relative risk (RR) 1.5; 95% 
confidence interval (CI) 1.08–2.09].168
For ADA, fewer data are available. Placental transfer has been 
shown in small studies.121,123 Pregnancy outcomes in these stud-
ies were available for only a limited number of pregnancies and, 
together with the report from PIANO study, no increased rate of 
adverse pregnancy outcomes has been documented for pregnancies 
exposed to ADA.168 Interestingly, ADA 40 mg every other week or 
weekly was administered to 14 women with recurrent miscarriage to 
prevent a new miscarriage. Four pregnancies resulted in miscarriage; 
in the other 10 pregnancies no abnormalities occurred.169
Although intra-uterine exposure to IFX or ADA does not seem to 
increase the risk of adverse pregnancy outcomes, the long-term effect 
on the developing immune system remains unknown. Therefore, in 
specific cases, discontinuation of the treatment during pregnancy 
might be considered to limit the intra-uterine exposure to these 
agents. A prospective study comprising 29 pregnancies with inten-
tional discontinuation of anti-TNF agents during the second trimes-
ter demonstrated that this early discontinuation does not increase 
the risk of the flare of maternal disease and results in significantly 
lower levels of IFX in cord blood.123
Certolizumab pegol is a PEGylated Fab′ fragment of a humanized 
anti-TNFα monoclonal antibody. Fab′ fragments cross the placenta 
by passive diffusion, unlike the active transfer of IgG1 antibodies, 
so the rates of transfer across the placenta in the third trimester are 
likely to be lower than with IFX or ADA. A study of pregnant rats 
receiving a murinized IgG1 antibody of TNFα and a PEGylated Fab′ 
fragment of this antibody demonstrated much lower drug concen-
trations in the infant rat and breast milk with the Fab′ fragment, 
compared with the full antibody.170 In the human situation, a study 
including 10 pregnancies exposed to certolizumab showed very low 
(less than 2 µg/ml) to undetectable levels of certolizumab in cord 
blood.173 Experiences with the use of certolizumab pegol during 
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pregnancy are more limited than with IFX or ADA, but experimen-
tal data in animals and first clinical data do not reveal an increased 
teratogenic risk in humans.121,168,171
Data on the initiation of anti-TNF treatment during pregnancy are 
scarce. Seven cases of infliximab initiation during pregnancy as part of 
two retrospective cohort studies,112 and one case report of successful 
treatment of steroid-refractory disease with infliximab during preg-
nancy172 have been reported thus far. Despite the lack of data, keeping 
in mind the maternal and fetal risks related to active disease, in specific 
cases of steroid-refractory disease or in case of significant adverse events 
of steroids, the initiation of an anti-TNF agent should be considered. 
Since certolizumab has very limited placental transfer, this agent may be 
preferred in case of initiation of anti-TNF treatment during pregnancy.
5.2.7. Metronidazole, ciprofloxacin
Metronidazole and the quinolones have limited benefit for long-term 
treatment of IBD. Short courses of these medications may be benefi-
cial in the treatment of pouchitis and perianal disease and are low 
risk in the pregnant patient.
Metronidazole is used for treatment of active CD as well as perianal 
disease. This medication does not increase risk of spontaneous miscar-
riage or congenital anomalies,173,174 although infants of women exposed 
to metronidazole in the second to third months of pregnancy have 
shown higher rates of cleft lip with or without cleft palate. However, a 
recent cohort study with 922 pregnant women treated with metronida-
zole at different stages of pregnancy showed no adverse pregnancy out-
comes, including congenital malformations, related to metronidazole.175
Human studies with ciprofloxacin have not shown an increase 
in spontaneous miscarriage or congenital abnormality incidence.176 
However, animal studies demonstrate musculoskeletal abnormalities 
induced by this medication class.177 Fluoroquinolones have a high 
affinity for bone tissue and cartilage, and may cause arthropathies 
in children. Although they are thought to have minimal risk overall, 
they should be avoided in the first trimester.
5.3. Nutritional deficiencies
There are no specific nutritional recommendations in pregnant 
women with IBD beyond those of a control population or specific 
situations (such as an obstructed CD patient). Scarce reports in older 
literature addressed hyperalimentation as a method of sustaining 
pregnancy in IBD patients. The data do not justify specific recom-
mendations. Folic acid according to national guidelines should be 
commenced in all IBD patients in anticipation of a pregnancy178–184 
and, although data are lacking, higher doses could be adminis-
tered to women with known small bowel disease. Nutritional defi-
ciencies should be assessed and treated as required. World Health 
Organization recommendations for pregnancy should be followed.185
5.4. Surgery during pregnancy
Indications for surgery in pregnant women with IBD do not differ 
from nonpregnant women. In severely ill patients, continued illness is 
a greater risk to the fetus than surgical intervention.186 In women with 
CD, obstruction, perforation, hemorrhage, abscess, or ongoing disease 
activity despite medical treatment, are indications for surgery and are 
no different to those for nonpregnant women.125,186–188 In UC, the main 
indication would be severe colitis not responding to medical therapy. 
Procedures have included proctocolectomy, hemicolectomy, segmental 
resection, and ileostomy. A temporary ileostomy is generally preferred, 
to reduce the risk of postoperative complications after primary anas-
tomosis.188 In the case of UC, the indications for surgery are severe 
disease not controlled by medical therapy, and urgent premalignant 
or malignant disease, discussed on an individual basis. With respect to 
timing of surgery during pregnancy, there is seldom room for a choice. 
Surgery is relatively safe in all trimesters but there are some limited 
series reporting on spontaneous miscarriage in the first trimester and 
on preterm labour when operation in the third trimester.188
5.5. Counseling during pregnancy
Studies evaluating the impact of medication discontinuation on the 
relapse rate of pregnant IBD patients are lacking. Only two studies eval-
uated adherence to maintenance therapy during pregnancy and reported 
rates of 59% and 72% among pregnant women with UC and with CD, 
respectively.189,190 The most frequent reason for non-compliance during 
pregnancy is the fear of medication adverse effects on the fetus.7,189,191–193 
Recently, it has been shown that patient knowledge of reproductive 
aspects of IBD improves after a single education session194 but, thus far, 
no studies have evaluated the real impact of the counseling on medica-
tion adherence and relapse rate during pregnancy. However, it has been 
documented that a tailored approach in counseling in general results in 
an increased adherence in the long term,195 and thus this approach might 
be useful in maintaining adherence among pregnant IBD patients as well.
6. Lactation
6.1. Influence of lactation on disease activity and 
child outcome
Women with IBD are as likely as the general population to breastfeed 
their infants; the mean duration of the breastfeeding period is shorter 
than in the general population.196,197 Breastfeeding is not associated with 
an increased risk of disease flare and may even provide a protective 
effect against disease flare in the postpartum year.70,198–201 However, in 
one study, lactation was associated with an increase in disease activity; 
but medication cessation was a relevant confounding factor.202
It is reported that breastfeeding might be protective against the 
development of early onset of IBD in children.201 Thus, breastfeeding 
is suggested when possible, as it may have a protective effect against 
development of IBD in the offspring; however, the quality of existing 
ECCO Statement 5E
Indications for surgery in pregnant women with IBD are 
the same as for non-pregnant patients. In the severely ill 
patient, continued illness is a greater risk to the fetus than 
surgical intervention [EL4]
ECCO Statement 5F
Discontinuation of maintenance therapy may result in dis-
ease relapse and appropriate counseling of the patient, 
ideally prior conception, is helpful in preventing non 
adherence to the treatment due to fear of potential harm 
to the unborn child [EL5]
ECCO Statement 6 A
Lactation does not independently affect disease activity 
in IBD [EL 2]
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data is generally poor. These findings need to be investigated in well-
designed prospective studies.
There is also limited evidence that breastfeeding may be associ-
ated with a more beneficial gut microbe profile, as it seems to be 
associated with highest numbers of bifidobacteria and lowest num-
bers of C. difficile and E. coli,203,204 which may help protect against 
the development of IBD. Formula milk feeding or breastfeeding do 
not seem to differ in terms of onset of intestinal inflammation,205 but 
controversial data exist.206
6.2. Medical treatment during lactation
For a summary of risks of frequent IBD medications used during 
lactation, see Table 1.
Sulfasalazine is of low risk during breastfeeding. The sulfapyri-
dine moiety is absorbed in minimal amounts and is excreted in milk, 
but the milk/serum ratio is acceptable.207 This low risk of aminosal-
icylates has been confirmed in prospective trials.208–210
As metronidazole211 and ciprofloxacin212 are excreted into breast 
milk, neither drug is considered appropriate during the breastfeed-
ing period.
Prednisone and prednisolone result in low human breast milk 
concentrations. To minimize exposure, a 4-h delay after oral dosing 
could be recommended.213,214
Very small amounts of AZA/6-MP metabolites (nanomolar con-
centrations of 6-methyl mercaptopurine and thiouric acid) appear 
in breast milk as reported in several case reports.215–217 There is a 
great inter-individual variability in the absorption and metabolism 
of AZA and 6- MP,218,219 which influences the exposure of the indi-
vidual child. Investigation of a group of 11 mothers taking AZA 
during pregnancy and lactation, and another of 12 patients without 
using any immunosuppressive therapy, showed that in the 15 breast-
fed babies followed up to 4.7 years of age, no increased infection 
risks for the children were observed.220
Limited data suggest that infant exposure to tacrolimus via 
breast milk is low and therefore this should be discussed.221 There 
are no data to support the use of ciclosporin in breastfeeding 
because therapeutic blood concentrations in the breastfed infant 
are described.222 It is not known whether thalidomide is excreted 
in breast milk.
In 4 women treated with IFX while breastfeeding, the IFX anti-
body could not be detected in breast milk and the IFX was also 
not detectable in the sera of three infants.223,224 Interestingly, in one 
observation 6 weeks after delivery, the breastfed infant’s serum 
infliximab level was 39.5 µ/ml after the mother had received IFX 
until 2 weeks before delivery, but IFX was not detected in the breast 
milk.166 In more recent reports, IFX was detected in the breast 
milk obtained postpartum from three breastfeeding patients with 
Crohn’s disease, but at doses 200 times lower than serum levels. 
No impact on the infection rate in the newborn was found.225 ADA 
has been reported to be excreted in low levels in the milk of a nurs-
ing mother; however, no data are available about serum levels in 
infants.226
Data on the effects of maternal biologicals on the breast-
fed infant are scarce, but until now no adverse effects have been 
reported. As for all drugs, the unknown long-term side effects of the 
drugs should be discussed with the patient. IFX can be detected in 
the breast milk of nursing mothers, but the level of oral absorption 
by the infant is unclear. Drug and antibody monitoring in breast 
milk and infants are possible; however, the relevance of those levels 
remains unclear.
7. Special considerations
7.1. Influence of IBD on sexuality
There are conflicting data on the impact of IBD on sexuality.227,228 
It is likely that symptoms and disease activity can affect sexuality, 
and female patients with IBD are reported to have a higher likeli-
hood of symptoms such as penetration pain, low libido, and men-
strual abnormalities.229
Psychological factors may also play a role and depression has 
been found to be more prevalent among people with IBD230 and 
is a predictor for low sexual function.231 Women with IBD report 
significantly reduced sexual activity and libido compared with 
men.232 There is conflicting evidence on the effect of surgery on the 
sexual function of women with IBD, with some studies reporting 
a significant reduction in libido, body image, and sexual activity 
after surgery233 and other studies reporting no difference despite 
an increase in dyspareunia.232–234 In men, sexuality seems to be less 
affected.231,234 Rare complications, particularly from pelvic surgery, 
include loss of or retrograde ejaculation. However, sexual function 
seems to be preserved or even increased after surgery.27,234,235 This 
can be attributed to improvements in general health after thera-
peutic surgery and/or improvements in psychosexual health lead-
ing to increased sexual desire following, for example, reversal of 
stoma which has been shown to have a negative impact on sexual 
function.236,237
7.2. Oral contraceptive use in IBD
There are no studies assessing the efficacy of oral contracep-
tives (OCs) in women with IBD. OC steroids are mainly absorbed 
from the small bowel, and contraceptive efficacy depends on thiss 
absorptive capacity. Enhanced passage of gastrointestinal contents 
or impaired absorption may thus contribute to contraceptive failures 
in patients who have chronic inflammatory disease, diarrhea, or jeju-
noileal bypass. Therefore it can be hypothesized that the efficacy of 
OCs may be reduced in women with CD who have small bowel dis-
ease and malabsorption. The general advice for women using OCs, 
who have been vomiting or have had severe diarrhoea for more than 
ECCO Statement 6B
5-ASA derivatives [EL3], thiopurines [EL3], anti-TNFs 
[EL4], and corticosteroids [EL4] are of low risk for breast-
fed infants
ECCO Statement 7A
Data on the effect of IBD on the sexual function are conflict-
ing [EL4]. A negative effect on sexual function is associ-
ated with low mood, but disease activity is also implicated 
[EL4]. In males and females, sexual function seems to be 
preserved or even increased after surgery [EL 2]
ECCO Statement 7B
There are no data to support an effect of IBD on the effi-
cacy of oral contraceptives [EL4]. Oral contraceptives do 
not aggravate the activity of IBD [EL3]
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24 h, is to follow instructions for missed pills.238 One large prospec-
tive cohort study and some case-control studies showed no effect of 
OCs on the activity of IBD.238–240 
Contraception is highly efficient and safe in preventing unwanted 
pregnancy.
In an IBD patient, a clinical decision regarding the use of contra-
ceptives should be made on an individual basis.
Using OCs has long been associated with a modest increase in the 
chance of developing IBD, specifically CD.241 In the older literature 
a hypothesis was raised that OCs may play a role in the etiology 
of IBD through a process of multifocal, microvascular gastrointes-
tinal infarction.242 Evidence regarding the effect of thrombosis risk 
that would be specific to IBD patients is vague. Hormonal therapy is 
one of the most significant prothrombotic risk factors. OCs induce 
resistance to activated protein C,243 increase levels of procoagulant 
proteins (factors II, VII, VIII, and fibrinogen),244 decrease levels of 
antithrombin, protein S, tissue factor pathway inhibitor, and fibrino-
lytic proteins, and increase markers of coagulation and fibrinolysis 
activation.244–246 The thrombotic risk associated with OC use var-
ies with the time interval since starting treatment but is highest in 
the first year of use, especially in women who have a prothrombotic 
defect.246,247 Adolescent girls who have coexisting thrombophilic con-
ditions, such as systemic lupus erythematosus, a history of thrombo-
embolism (TE), or other conditions, have relative contraindications 
to combination hormonal contraceptive methods, because these 
medications place them at higher risk for TE.248–251 Inflammation is a 
thrombophilic condition, due to elevated factor VIII. IBD specifically 
is considered a thrombophilic condition.252 Thus, in an IBD patient 
a clinical decision regarding the use of OCs should be made on an 
individual basis.
7.3. Venous thromboembolism risk in pregnancy
Pregnancy increases the risk of venous thromboembolism (VTE) 
by 4–6 fold253 and is a leading cause of direct maternal death in devel-
oped countries.254 The time of highest risk is in the first 6 weeks of 
the postnatal period.255 IBD patients, particularly those hospitalized 
with active disease, are at increased risk for VTE.93,256 Hospitalized 
pregnant IBD patients have an increased risk of VTE compared 
with their non-IBD pregnant controls: for CD, odds ratio (OR) 6.12 
(95% CI, 2.91–12.9) and for UC, OR 8.44 (95% CI, 3.71–19.2). 
Low molecular weight heparin in a prophylactic dose reduces the 
risk of VTE in medical and surgical patients by 60–70%.257 Low 
molecular weight heparin has been shown to be safe and efficacious 
in the pregnant population.258 Therefore consideration of the use of 
prophylactic low molecular weight heparin in pregnant IBD patients 
experiencing a relapse and/or admitted to hospital is strongly rec-
ommended. All women should undergo a documented assessment 
of risk factors for venous thromboembolism (VTE) in early preg-
nancy or before pregnancy. This assessment should be repeated if 
the woman is admitted to hospital for any reason and again after 
delivery.259
7.4. Cervical cancer screening: please see guidelines 
on opportunistic infections statement (OI 4F) 
For text please see Second European Evidence-based Consensuson 
the prevention, diagnosis, and managementof opportunistic infec-
tions in inflammatory bowel disease.260
7.5. Endoscopy during pregnancy
ECCO Statement 7C
IBD is a thrombophilic condition, however the effect is 
modest [EL3]. Oral contraceptives place patients with 
thrombophilic conditions such as IBD and smoking at 
higher risk for thromboembolism [EL1]
ECCO Statement 7D
Risk assessment for VTE [venous thromboembolism] 
should be performed in the pregnant patient with IBD 
[EL 4]. Consideration of prophylactic low molecular weight 
heparin should be given in any pregnant IBD patient expe-
riencing a relapse, admitted to hospital, or if additional 
risk factors are identified [EL3]
ECCO Statement 7E / OI 4F
Regular gynecologic screening for cervical cancer is 
strongly recommended for women with IBD, especially 
if treated with immunomodulators [EL2]. In patients with 
extensive cutaneous warts and/or condylomata, discon-
tinuation of immunomodulator therapy should be consid-
ered [EL5]. Routine prophylactic HPV [human papillovirus] 
vaccination is recommended for females and males 
according to national guidelines [EL2]. Current or past 
infection with HPV is not a contraindication for immu-
nomodulator therapy [EL2] 
ECCO Statement 7G
Gastroscopy [EL3], sigmoidoscopy/colonoscopy, and 
ERCP [endoscopic retrograde cholangiopancreatography] 
[EL4] are generally considered to be safe in pregnancy; 
however, these procedures should only be done when 
there is a strong indication and should be performed in 
the second trimester whenever possible [EL5]. Hemostasis 
measures are safe and should be carried out with precau-
tions [EL5]
ECCO Statement 7H
Procedure time and radiation exposure should be kept 
to a minimum [EL4]. Endoscopic procedures should be 
managed in conjunction with specialists in obstetrics and 
obstetric anesthesia [EL5]. Pregnant patients should be 
placed in the left pelvic tilt or left lateral position before, 
during and after the endoscopic procedure, to avoid vena 
caval compression [EL5]. Presence of fetal heart sounds 
should be confirmed before sedation is begun and after 
the endoscopic procedure [EL5]
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Limited evidence exists regarding the utility and safety of endos-
copy in the pregnant woman with IBD. Maternal considerations 
include the increased risk of aspiration following gastroscopy due 
to lower esophageal sphincter incompetence. Fetal considerations 
include the preservation of adequate maternal oxygenation and blood 
pressure to allow optimal placental perfusion. Therefore pregnant 
women undergoing endoscopy should have their saturations moni-
tored throughout the procedure, and the minimum dose of sedat-
ing drug necessary for an adequate effect should be used. Pregnant 
patients in the second or third trimester should be placed in the left 
pelvic tilt to reduce the risk of vena caval compression and thus mini-
mize hypotension. Due to these potential complications, endoscopy in 
pregnancy should be reserved for strong indications. However, endos-
copy does appear to offer a relatively safe alternative to radiologic 
or surgical intervention.261–264 Case series and case-controlled studies 
have shown that gastroscopy is safe and effective, with no evidence for 
this procedure inducing labor.265,266 Likewise, small case series of colo-
noscopy in pregnancy showed no evidence of adverse outcome.267,268
Endoscopic retrograde cholangiopancreatography (ERCP) 
in pregnancy has been reported in several case series.269–271. These 
studies suggest that ERCP is safe in pregnancy, with no increased 
incidence of congenital malformations, fetal distress, or incidence 
of precipitating labor. However, there may be a higher risk of post-
ERCP associated pancreatitis,269,272–274 although this did not alter the 
overall pregnancy outcome in these studies. Radiation dose should 
clearly be kept to a minimum; in the majority of studies the dose 
did not exceed the accepted threshold of 10 mGy, but this was not 
always the case. Recently several case reports and a small study on 
six pregnant women described the successful application of ERCP 
without radiation.275
The benefit of epinephrine, electricity and contrast dye276 in the 
appropriate situation outweigh the risks. The risk of use of poly-
ethelene glycol for preparation is considered low.277 Sodium phos-
phate preparations have no data but are a potential harm and should 
be avoided.278
Meperidine is commonly used in endoscopy for analgesia and seda-
tion. It is rapidly transferred across the placenta, but in two large 
studies of 268 mothers279 and 62 newborns,280 respectively, no tera-
togenicity from meperidine administration during the first trimester 
was reported. Meperidine can cause diminished fetal beat-to-beat 
cardiac variability that lasts for approximately 1 h after maternal 
intravenous administration.281 This can also be interpreted as a sign 
of fetal distress; however, this side effect is reversible, transient, and 
not a poor prognostic indicator. Meperidine, when used sparingly, is 
approved by the American Academy of Pediatrics for use in breast-
feeding mothers.
Fentanyl is commonly administrated during labor and is consid-
ered safe, although case reports note neonatal respiratory depres-
sion, muscle rigidity,282 and opioid withdrawal283 as potential side 
effects. Fentanyl is excreted in breast milk, but its low bioavailability 
to the breastfeeding infant makes it acceptable to breast feed follow-
ing its use.284
Propofol use during endoscopy is increasingly common. 
However, it has not been extensively studied in women in the first 
and second trimesters and therefore is not recommended for use 
during this time. Small amounts of propofol are excreted into breast 
milk and colostrum, but the concentration is considered negligi-
ble.285 The benzodiazepines, diazepam and midazolam, should be 
avoided particularly during the first trimester. Midazolam, the pre-
ferred benzodiazepine for endoscopy, crosses the human placenta, 
but fetal serum levels increase to only about one- to two-hirds of 
maternal serum levels after oral, intramuscular, or intravenous 
maternal administration.
Midazolam and its metabolite are excreted into milk, but there 
was minimal exposure if breastfeeding was held for 4 h after admin-
istration of a 15-mg dose.285,286
8. Recommendations from the 
Consensus group
It was shown in a small case series that the majority of IBD 
patients with conception plans require medication for which limited 
information on the safety of peri-conceptional use is available.287 In 
addition, reproductive wishes lead to medication changes in one-
third of these patients. Therefore the working group feel it is impor-
tant to counsel all IBD patients wishing to conceive. Furthermore, if 
a flare occurs in the third trimester, the working group feel that these 
women are in need of specialized multidisciplinary care by a team 
with experience in treating active IBD in pregnancy. This team should 
include gastroenterologists, obstetricians and pediatricians.287.
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